Product information and disease descriptionProduct descriptionProduct information
Special populations
12 evidence topics · 9 sources
Renal impairment: minor renal elimination
Renal impairment: single-dose study in severe renal impairment
Renal function range enrolled in AMPLITUDE
Hepatic impairment: single-dose study in mild or moderate hepatic impairment
Pediatric population: adolescents added to the phase 3 portion of AMPLITUDE
Pediatric population: acceptability of the tablet formulation
Pregnancy and childbearing potential: exclusion from the phase 1 studies
“In both studies, we enrolled healthy men and women of non-childbearing potential who were at least 18 years of age with body weight of >50 kg and body mass index (BMI) 18.0 to 32.0 kg/m2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A limitation of these studies, like most phase 1 studies, is that participants were predominantly men (owing to exclusion of women of childbearing age).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote